{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-260923","form_type":"8-K","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2024-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.381081+00:00","generated_at":"2026-05-29T23:16:27.359696+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NewAmsterdam Pharma reports Phase 3 BROOKLYN trial: LDL-C reduced 36.3% vs placebo at day 84, Lp(a) reduced 45.9%","bullets":["LDL-C mean reduction vs placebo 36.3% at day 84 (p<0.0001), sustained at 41.5% at day 365.","Lp(a) mean reduction vs placebo 45.9% at day 84; total LDL particles reduced 52.5% at day 180.","Safety comparable to placebo; discontinuation rate 7.6% for obicetrapib vs 14.4% for placebo.","Trial enrolled 354 HeFH patients; mean baseline LDL-C 123 mg/dL despite high statin use (79%) and ezetimibe (54%).","Data presented at AHA 2024; topline from TANDEM and BROADWAY studies expected Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-260923","json":"https://secwatch.observer/filing/0001193125-24-260923.json","markdown":"https://secwatch.observer/filing/0001193125-24-260923.md","text":"https://secwatch.observer/filing/0001193125-24-260923.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000119312524260923/0001193125-24-260923-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000119312524260923/d840591d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T23:16:27.359696+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}